Abstract Library

#4473 Somatostatin analogue delayed the recrudescence of stomach NET: A real-world study

Introduction: Type 1 gastric NENs (g-NENs) are common and relapse easily. Somstostatin analogues (SSAs) can inhibit gastrin secretion and cell proliferation. While the usage of SSAs in g-NENs is still controversial.

Conference:

Presenting Author: Cai W

Authors: Cai W, Zhang J, Ge W, Hu H,

Keywords: somatostatin analogue, Type 1 gastric NEN, real-world study,

#4400 Analysis of clinicopathologic features and prognosis of 8096 patients with gastric neuroendocrine neoplasms

Introduction: Gastric neuroendocrine neoplasms (G-NENs), as rare tumours, continue to increase in morbidity and mortality. The specificity of the clinical features of G-NENs has led to a lack of awareness of this disease.

Conference:

Presenting Author:

Authors: Han D, Du H,

Keywords: Gastric neuroendocrine neoplasm, Clinicopathologic features, Prognosis,

#4329 Multivariate survival analyses of 544 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC) given first-line chemotherapy (NORDIC NEC 2)

Introduction: Digestive high-grade neuroendocrine neoplasms (HG-NEN) are rare and consist of neuroendocrine tumours G3 (NET G3) and neuroendocrine carcinomas (NEC). They differ in clinical and molecular characteristics, response to treatment and prognosis. Limited prospective data are available on prognostic factors for survival in patients given first-line chemotherapy outside of clinical trials.

Conference:

Presenting Author:

Authors: Sorbye H, Hjortland G, Vestermark L, Ladekarl M, Svensson J,

Keywords: neuroendocrine neoplasm, neuroendocrine carcinoma, digestive, high-grade, neuroendocrine tumour grade 3,

#3949 Real-world study of Surufatinib combined with hepatic artery infusion chemotherapy (HAIC) for high-grade neuroendocrine neoplasm

Introduction: Current therapeutic schedules of liver metastasis-dominated extrapulmonary high-grade neuroendocrine neoplasm (HG-NEN) have limited clinical benefits and liver metastasis progression is the main cause of death. Surufatinib (SUR, a selective VEGFRs, FGFR1 and CSF-1R inhibitor) showed promising antitumor activity in neuroendocrine neoplasm.

Conference:

Presenting Author:

Authors: Wang Y, Yu H, Yang D, Liu H, Yao W,

Keywords: Real-world study, surufatinib, hepatic artery infusion chemotherapy, high-grade neuroendocrine neoplasm,

#3933 Surufatinib plus Sintilimab and IBI310 in patients with high-grade advanced-neuroendocrine neoplasm (HG-NEN): A multicenter, single arm phase 2 study

Introduction: Surufatinib (SUR, a selective VEGFRs, FGFR1 and CSF-1R inhibitor). Preclinical and clinical studies have shown that SUR is the best partner of immune checkpoint inhibitors (ICI).

Conference:

Presenting Author: Zhang P

Authors: Zhang P, Wang Y, Li J, Shen L, Lu M,

Keywords: Surufatinib, Sintilimab, IBI310, high-grade advanced-neuroendocrine neoplasm,